Henry Schein (HSIC)
NASDAQHealth CareMedical DistributionSnapshot 2026-07-07
$86.84+0.25%
Close 2026-07-07 · 1-day change
Reading HSIC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HSIC free→NASDAQHealth CareMedical DistributionSnapshot 2026-07-07
Reading HSIC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HSIC free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady growth. The current thesis is stable, supported by strong financial performance and management's commitment to growth targets.
The market appears to have priced in a neutral valuation, suggesting that HSIC is seen as cheap compared to its peers. However, there is a slight expectations gap, indicating that some cautious sentiment may be present.
Fundamentals are likely to continue on a positive trajectory, as management is on track to achieve its sales and EBITDA growth targets. However, there is a moderate risk of missing expectations, given recent industry trends.
The thesis hinges on the performance of sector bellwethers like MCK, CAH, and COR. If these companies continue to perform well, it could support HSIC's growth. Conversely, any negative guidance from these peers could impact HSIC's momentum.
Overall, HSIC is positioned well for the next few years, but its success will depend on broader sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat and the expectation of achieving 3% to 5% sales growth in 2026, which reinforces the company's growth outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Filing the Form 10-Q shows the company follows Nasdaq rules. This helps build investor trust.
Confirms:The Form 10-Q is filed by the end of November 2023 as expected.
Disproves:The Form 10-Q is not filed by the end of November 2023.
Why it matters: Hitting the growth target is key for keeping investor trust and helping stock performance.
Confirms:Q2 2026 revenue growth reported at or above 3%.
Disproves:Q2 2026 revenue growth reported below 3%.
Why it matters: Earnings results will show how sales are growing. They will also share plans for 2026.
Confirms one read:Q2 2026 non-GAAP EPS growth is reported above the low to mid-single digits.
Confirms the other:Q2 2026 non-GAAP EPS growth is reported below the low to mid-single digits.
Why it matters: Keeping EBITDA growth strong is important. If it drops below 5%, there may be problems.
Confirms:EBITDA growth is below 5%.
Disproves:EBITDA growth reported at 5% or higher.
Why it matters: Updates on the partnership may show new growth chances and better operations.
Confirms:Henry Schein shares specific actions or results from the partnership with KKR.
Disproves:No news or progress on the partnership with KKR after several months.
Why it matters: KKR's investment signals strong confidence in Henry Schein's growth strategy. It may lead to new opportunities.
Confirms:KKR completes its additional $250 million investment in Henry Schein by the end of Q2 2026.
Disproves:The investment does not close by the end of Q2 2026 due to regulatory or other issues.
Why it matters: Reaffirming EPS guidance shows confidence in earnings. A failure to do so raises doubts.
Confirms:Management reaffirms EPS guidance for 2026.
Disproves:Management cuts its EPS guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Confirming plans shows management's confidence. This can help the stock perform better.
Confirms:Management reaffirms 2025 non-GAAP EPS growth guidance at the earnings call in February 2025.
Disproves:Management revises down the 2025 non-GAAP EPS growth guidance during the earnings call.
Why it matters: Updates on the KKR partnership can show chances for growth and better operations.
Confirms:Public announcements will share details about the KKR partnership's plans or results.
Disproves:No important updates or plans have been announced about the KKR partnership.
Why it matters: If sector growth drops, it could impact Henry Schein's performance. It’s a sign of broader issues.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains above its median.